Search

Displaying results 271 - 280 of 10000 in total
  1. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863] … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

    Products: ANASTROZOLO EG, ANASTROZOLO SUN
  2. Drug

    Riluzole

    go.drugbank.com/drugs/DB00740
    ApprovedInvestigational

    A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.

    Categories: Compounds used in a research, industrial, or household settingProducts: RILUZOLO SUN, RILUZOL SUN 50MG
  3. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

    Categories: Compounds used in a research, industrial, or household settingProducts: Skin N Clean
  4. Drug

    Citalopram

    go.drugbank.com/drugs/DB00215
    ApprovedInvestigational

    [A261316] Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.[L5230] … Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression.

    International brands: RecitalProducts: Sig-citalopram, CITALOPRAM EG
  5. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma.

    Products: TEMODAL 140MG HKP IN BTL, TEMODAL 180MG HKP IN BTL
  6. Drug

    Budesonide

    go.drugbank.com/drugs/DB01222
    ApprovedInvestigational

    [A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598] It is also available in a combination product with [formoterol].[L10619]

    Mixtures: BUDESONIDE E FORMOTEROLO SANDOZ, BUDESONIDE E FORMOTEROLO SANDOZProducts: BUDESONIDA 50 MCG INHALADOR EN AEROSOL, PULMICORT RESPULES (1 MG IN 2 ML)
  7. Drug

    Levamisole

    go.drugbank.com/drugs/DB00848
    ApprovedInvestigationalVet approvedWithdrawn

    [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120]

    Products: OBAT CACING NO.17 KAM CEK SAN, PVP- LEVAMISOLE POUR-ON SOLUTION 20 %w/v
  8. Drug

    Bendamustine

    go.drugbank.com/drugs/DB06769
    ApprovedInvestigational

    Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. … Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

    Products: Bendamustin Mylan 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
  9. Drug

    SIG-205

    go.drugbank.com/drugs/DB18548
    Experimental

    SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer

  10. Drug

    SIG-207

    go.drugbank.com/drugs/DB18547
    Experimental

    SIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified